BCR::ABL1 Fusion, t(9;22)(q34;q11.2), FISH !!! NOTE: The contents are valid only for: 11/28/2024 !!!
| WSLH Department: | Cytogenetics |
| WSLH Test Code: | 881F61 |
| Day(s) Performed: | Monday-Friday 7:45 AM - 4:30 PM, Saturday 7:45 AM - 12:00 PM |
| Turn-around Time: | Approximately 4-6 days. (Reports are issued Monday-Friday 7:45 AM - 4:30 PM) |
| Recommended Uses: | Detection of the BCR::ABL1 fusion associated with chronic myeloid leukemia (CML) and acute lymphocytic leukemia (ALL). Aids in diagnosis of hematologic disorders and for monitoring disease after treatment or bone marrow transplant. May be performed in conjunction with other FISH assays, quantitative or qualitative RT-PCR, chromosome analysis or as an independent test. |
| Contraindications: | |
| Additional Tests Performed: | |
| Patient Preparations: | |
| Specimen Requirements: | 0.5-1.0 ml early aspirate bone marrow OR 1-2 ml whole blood collected in sodium heparin vacuum type tube |
| Specimen Handling & Transport: | Store and transport specimens at room temperature (may transport with coolant during hot weather, >85 degrees F). DO NOT FREEZE. The laboratory must receive specimens within 24 to 48 hours of collection. |
| Collection Kit/Container: | |
| Collection Instructions: | **Bone marrow: 0.5-1.0ml bone marrow from 1st or 2nd aspirate. Material submitted for cytogenetic analysis must be from an early aspirate to avoid dilution with blood. Draw sodium heparin solution (1000 USP units/ml) into the syringe to be used for aspiration and then expel (over-heparinization is toxic to the cells). Transfer the marrow to a sterile, Na-Heparin vacuum type tube for delivery to State Lab. If an aspirate is unsuccessful, a 10mm bone core biopsy may be submitted in a sterile transport medium with Na-Heparin. **Blood: Draw blood using aseptic techniques into a sterile Na-Heparin vacuum type tube. Invert tube to mix. If using larger tubes, draw to full volume to avoid over-treatment with heparin. |
| Unacceptable Conditions: | Bone marrow/blood that is clotted or hemolyzed is not acceptable. Bone marrow/blood must not be frozen. Plasma and serum are not acceptable. |
| Requisition Form: |
Cytogenetics Lab Neoplasia Diagnosis Form #132
|
| Required Information: | Laboratory regulations require the following minimum information to be provided on the requisition form for a specimen to be accepted for testing: Patient name or unique identifier; date and time of collection, patient date of birth and sex, specimen type/site of collection, test request(s), reason for referral, clinician name and UPIN/NPI, and address for reporting results. Please be certain that name/identifier on the form matches that on the specimen label. |
| Results Include: | Number of nuclei examined, percent positive for BCR::ABL1 rearrangement, and the reference range for false positives based on the number of cells with an abnormal signal pattern in 200 control cells. Result written using current International System for Human Cytogenetic Nomenclature (ISCN) and interpretation of results. |
| Limitations: | Failure to identify an abnormal clone by FISH does not rule out the presence of other abnormalities in the specimen. This probe will not detect small deletions or duplications or base pair changes. |
| Additional Tests Recommended: | Qualitative and quantitative RT-PCR assays are available to detect Major and minor BCR::ABL1 fusion transcripts associated with t(9;22)(q34;q11.2) recurrent in CML and ALL. |
| Additional Comments: | If FISH assay is not performed in conjunction with chromosome analysis there is an additional charge for processing the specimen. |
| Methodology: | Fluorescence in situ hybridization performed on interphase nuclei using dual fusion DNA probes (LSI BCR::ABL1 dual color, dual fusion; Abbott Molecular) specific for the ABL1 gene in 9q34 and the BCR gene in 22q11.2. |
| Includes: | FISH analysis of 200 cells for fusion of the BCR and ABL1 genes |
| CPT Code: | 88271x2, 88275 |
| Price: | For pricing information, please call 608-262-0402. |